Retinoids and tamoxifen in breast cancer chemoprevention

Alberto Costa, Virgilio Sacchini, Andrea Decensi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Chemoprevention is a new branch of oncology which aims to use chemical agents to reduce the incidence of malignant diseases in humans. On the basis of a growing mass of experimental data, it is now felt that the importance of early, precursor lesions of clinically symptomatic cancer should be recognized. Just as in cardio-vascular disease, there is now major emphasis on the natural history of tumors and some authors believe that the actual disease process is carcinogenesis, rather than cancer. Indeed, as the chemoprevention of cardiovascular illness with pharmacological agents that either lower blood cholesterol or prevent platelet aggregation is wide-spread, the effectiveness of different chemical compounds in preventing cancer or, at least in delaying its onset, is presently under investigation. For breast cancer, various agents have been suggested as having chemopreventive effects: vitamins C and E, difluoromethylor-nithine, selenium, retinoids and antiestrogens. Among retinoids, 4-(N-hydroxyphenyl) retinamide, fenretinide, is at present the most promising molecule, due to its ability to concentrate in the mammary gland. Attention has recently been focussed on tamoxifen because of its effectiveness in reducing the incidence of contralateral tumors in breast cancer patients. Finally, the recent discovery of the steroid receptor superfamily is expected to stimulate further research into combination chemoprevention (the use of multiple agents to achieve synergistic effects while diminishing toxicity). As retinoids and tamoxifen both increase the synthesis or activity of transforming growth factor-β, a cytokine which is a potent inhibitor of epithelial cell proliferation, tamoxifen and fenretinide are now proposed as the first model of combination chemoprevention in breast cancer.

Original languageEnglish
Pages (from-to)53-55
Number of pages3
JournalInternational Journal of Clinical & Laboratory Research
Volume23
Issue number1-4
DOIs
Publication statusPublished - Dec 1993

Fingerprint

Retinoids
Chemoprevention
Tamoxifen
Fenretinide
Breast Neoplasms
Tumors
Neoplasms
Chemical compounds
Oncology
Estrogen Receptor Modulators
Steroid Receptors
Cell proliferation
Transforming Growth Factors
Selenium
Platelets
Vitamin E
Ascorbic Acid
Incidence
Toxicity
Human Mammary Glands

Keywords

  • Breast cancer
  • Chemoprevention
  • Retinoids
  • Tamoxifen
  • Trials

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Retinoids and tamoxifen in breast cancer chemoprevention. / Costa, Alberto; Sacchini, Virgilio; Decensi, Andrea.

In: International Journal of Clinical & Laboratory Research, Vol. 23, No. 1-4, 12.1993, p. 53-55.

Research output: Contribution to journalArticle

Costa, Alberto ; Sacchini, Virgilio ; Decensi, Andrea. / Retinoids and tamoxifen in breast cancer chemoprevention. In: International Journal of Clinical & Laboratory Research. 1993 ; Vol. 23, No. 1-4. pp. 53-55.
@article{4f9f54ceacd447e485ba7f2da94a2185,
title = "Retinoids and tamoxifen in breast cancer chemoprevention",
abstract = "Chemoprevention is a new branch of oncology which aims to use chemical agents to reduce the incidence of malignant diseases in humans. On the basis of a growing mass of experimental data, it is now felt that the importance of early, precursor lesions of clinically symptomatic cancer should be recognized. Just as in cardio-vascular disease, there is now major emphasis on the natural history of tumors and some authors believe that the actual disease process is carcinogenesis, rather than cancer. Indeed, as the chemoprevention of cardiovascular illness with pharmacological agents that either lower blood cholesterol or prevent platelet aggregation is wide-spread, the effectiveness of different chemical compounds in preventing cancer or, at least in delaying its onset, is presently under investigation. For breast cancer, various agents have been suggested as having chemopreventive effects: vitamins C and E, difluoromethylor-nithine, selenium, retinoids and antiestrogens. Among retinoids, 4-(N-hydroxyphenyl) retinamide, fenretinide, is at present the most promising molecule, due to its ability to concentrate in the mammary gland. Attention has recently been focussed on tamoxifen because of its effectiveness in reducing the incidence of contralateral tumors in breast cancer patients. Finally, the recent discovery of the steroid receptor superfamily is expected to stimulate further research into combination chemoprevention (the use of multiple agents to achieve synergistic effects while diminishing toxicity). As retinoids and tamoxifen both increase the synthesis or activity of transforming growth factor-β, a cytokine which is a potent inhibitor of epithelial cell proliferation, tamoxifen and fenretinide are now proposed as the first model of combination chemoprevention in breast cancer.",
keywords = "Breast cancer, Chemoprevention, Retinoids, Tamoxifen, Trials",
author = "Alberto Costa and Virgilio Sacchini and Andrea Decensi",
year = "1993",
month = "12",
doi = "10.1007/BF02592283",
language = "English",
volume = "23",
pages = "53--55",
journal = "Ricerca in Clinica e in Laboratorio",
issn = "0940-5437",
publisher = "Springer Verlag",
number = "1-4",

}

TY - JOUR

T1 - Retinoids and tamoxifen in breast cancer chemoprevention

AU - Costa, Alberto

AU - Sacchini, Virgilio

AU - Decensi, Andrea

PY - 1993/12

Y1 - 1993/12

N2 - Chemoprevention is a new branch of oncology which aims to use chemical agents to reduce the incidence of malignant diseases in humans. On the basis of a growing mass of experimental data, it is now felt that the importance of early, precursor lesions of clinically symptomatic cancer should be recognized. Just as in cardio-vascular disease, there is now major emphasis on the natural history of tumors and some authors believe that the actual disease process is carcinogenesis, rather than cancer. Indeed, as the chemoprevention of cardiovascular illness with pharmacological agents that either lower blood cholesterol or prevent platelet aggregation is wide-spread, the effectiveness of different chemical compounds in preventing cancer or, at least in delaying its onset, is presently under investigation. For breast cancer, various agents have been suggested as having chemopreventive effects: vitamins C and E, difluoromethylor-nithine, selenium, retinoids and antiestrogens. Among retinoids, 4-(N-hydroxyphenyl) retinamide, fenretinide, is at present the most promising molecule, due to its ability to concentrate in the mammary gland. Attention has recently been focussed on tamoxifen because of its effectiveness in reducing the incidence of contralateral tumors in breast cancer patients. Finally, the recent discovery of the steroid receptor superfamily is expected to stimulate further research into combination chemoprevention (the use of multiple agents to achieve synergistic effects while diminishing toxicity). As retinoids and tamoxifen both increase the synthesis or activity of transforming growth factor-β, a cytokine which is a potent inhibitor of epithelial cell proliferation, tamoxifen and fenretinide are now proposed as the first model of combination chemoprevention in breast cancer.

AB - Chemoprevention is a new branch of oncology which aims to use chemical agents to reduce the incidence of malignant diseases in humans. On the basis of a growing mass of experimental data, it is now felt that the importance of early, precursor lesions of clinically symptomatic cancer should be recognized. Just as in cardio-vascular disease, there is now major emphasis on the natural history of tumors and some authors believe that the actual disease process is carcinogenesis, rather than cancer. Indeed, as the chemoprevention of cardiovascular illness with pharmacological agents that either lower blood cholesterol or prevent platelet aggregation is wide-spread, the effectiveness of different chemical compounds in preventing cancer or, at least in delaying its onset, is presently under investigation. For breast cancer, various agents have been suggested as having chemopreventive effects: vitamins C and E, difluoromethylor-nithine, selenium, retinoids and antiestrogens. Among retinoids, 4-(N-hydroxyphenyl) retinamide, fenretinide, is at present the most promising molecule, due to its ability to concentrate in the mammary gland. Attention has recently been focussed on tamoxifen because of its effectiveness in reducing the incidence of contralateral tumors in breast cancer patients. Finally, the recent discovery of the steroid receptor superfamily is expected to stimulate further research into combination chemoprevention (the use of multiple agents to achieve synergistic effects while diminishing toxicity). As retinoids and tamoxifen both increase the synthesis or activity of transforming growth factor-β, a cytokine which is a potent inhibitor of epithelial cell proliferation, tamoxifen and fenretinide are now proposed as the first model of combination chemoprevention in breast cancer.

KW - Breast cancer

KW - Chemoprevention

KW - Retinoids

KW - Tamoxifen

KW - Trials

UR - http://www.scopus.com/inward/record.url?scp=0027358075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027358075&partnerID=8YFLogxK

U2 - 10.1007/BF02592283

DO - 10.1007/BF02592283

M3 - Article

VL - 23

SP - 53

EP - 55

JO - Ricerca in Clinica e in Laboratorio

JF - Ricerca in Clinica e in Laboratorio

SN - 0940-5437

IS - 1-4

ER -